Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487546 · ClinicalTrials.gov registry record · NA
Repletion of Ergothioneine in Patients With Kidney Failure
A NA study of ESRD, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06487546: Recruiting NA study of ESRD, sponsored by Stanford University.
NCT06487546 is a NA study of ESRD that is actively recruiting participants, run by Stanford University. The registered enrollment target is 100 participants, below the 133-participant average among 13 other ESRD trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06487546, a NA study of ESRD, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.
Primary Outcome
ergothioneine levels will be measured in whole blood
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Ergothioneine
Study Locations (1)
California
- Veterans Affairs Palo Alto - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2029-12-01 |
| Phase | NA |
What NCT06487546 shows while recruiting
NCT06487546 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 13 other ESRD trials with a reported enrollment target (25% lower).
The record links to 1 condition, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which Ergothioneine is the first listed.
NCT06487546 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06487546 about?
NCT06487546 is a clinical study titled "Repletion of Ergothioneine in Patients With Kidney Failure". Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to le...
What is the current status of trial NCT06487546?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-04-01. Estimated completion is 2029-12-01.
What conditions does trial NCT06487546 study?
This clinical trial studies the following conditions: ESRD.
What interventions are being tested in trial NCT06487546?
The interventions under investigation include: Ergothioneine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06487546?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487546 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ESRD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06487546's enrollment target sits among peer trials
100 6th of 13 higher than 7 of 13 other ESRD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ESRD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
COMPLETED · NA
-
Comparison of Different Glucose Concentrations in Dialysate of Hemodialysis Patients
COMPLETED · NA
-
Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT
COMPLETED · NA
-
Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI